NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 57.74

-2.7%

Nov 12 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tuck	7/2/2007 12:09:21 PM
	Read Replies (1) of 507

Maxygen advances MAXY-G34 (PEG-GCSF) for treatment of Chemotherapy-Induced Neutropenia to P2 in breast cancer. Message 23668594 Nektar should have a little piece of this. Don't know if any milestone payments would be due. Likely to be small, if so. Edit: no milestones, just license fees (probably already booked) and royalties. The latter are probably low single digits, but hey, Neulasta/Neupogen sold almost $3 billion last year . . . Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next